BACKGROUND: Our aim was to study ways to improve IVF success rates in women with suspected endometrial receptivity defects. METHODS: We conducted a retrospective cohort study examining the effect of letrozole (aromatase inhibitor) on integrin expression as a marker of endometrial receptivity. We compared IVF outcomes in 97 infertile women who had undergone ανβ3 integrin assessment by immunohistochemistry in mid-luteal endometrial biopsies. Of 79 women undergoing standard IVF, 29 (36.7%) lacked normal integrin expression. Eighteen other women with low integrin were studied after receiving letrozole during early IVF stimulation. An independent set of ανβ3 integrin-negative patients (n = 15) who had undergone repeat endometrial biopsy for integrin testing while taking letrozole were re-evaluated. RESULTS: Clinical pregnancy and delivery rates were higher in women with normal ανβ3 integrin expression compared with those who were integrin negative [20/50 (40%) versus 4/29 (13.8%); P = 0.02 and 19/50 (38%) versus 2/29 (7%); P < 0.01, respectively]. In 18 women who received letrozole early in IVF, 11 conceived (61.1%; P < 0.001) compared with integrin-negative patients who did not receive letrozole. In integrin-negative women who were rebiopsied on letrozole, 66.7% reverted to normal integrin expression. Positive endometrial aromatase immunostaining using a polyclonal antibody was a common finding in infertile patients compared with controls. CONCLUSIONS: Lack of endometrial ανβ3 integrin expression is associated with a poor prognosis for IVF that might be improved with letrozole co-treatment. Prospective studies are needed to confirm and extend these findings but the data suggest that aromatase expression may contribute to implantation failure in some women.
BACKGROUND: Our aim was to study ways to improve IVF success rates in women with suspected endometrial receptivity defects. METHODS: We conducted a retrospective cohort study examining the effect of letrozole (aromatase inhibitor) on integrin expression as a marker of endometrial receptivity. We compared IVF outcomes in 97 infertilewomen who had undergone ανβ3 integrin assessment by immunohistochemistry in mid-luteal endometrial biopsies. Of 79 women undergoing standard IVF, 29 (36.7%) lacked normal integrin expression. Eighteen other women with low integrin were studied after receiving letrozole during early IVF stimulation. An independent set of ανβ3 integrin-negative patients (n = 15) who had undergone repeat endometrial biopsy for integrin testing while taking letrozole were re-evaluated. RESULTS: Clinical pregnancy and delivery rates were higher in women with normal ανβ3 integrin expression compared with those who were integrin negative [20/50 (40%) versus 4/29 (13.8%); P = 0.02 and 19/50 (38%) versus 2/29 (7%); P < 0.01, respectively]. In 18 women who received letrozole early in IVF, 11 conceived (61.1%; P < 0.001) compared with integrin-negative patients who did not receive letrozole. In integrin-negative women who were rebiopsied on letrozole, 66.7% reverted to normal integrin expression. Positive endometrial aromatase immunostaining using a polyclonal antibody was a common finding in infertilepatients compared with controls. CONCLUSIONS: Lack of endometrial ανβ3 integrin expression is associated with a poor prognosis for IVF that might be improved with letrozole co-treatment. Prospective studies are needed to confirm and extend these findings but the data suggest that aromatase expression may contribute to implantation failure in some women.
Authors: S K Goswami; T Das; R Chattopadhyay; V Sawhney; J Kumar; K Chaudhury; B N Chakravarty; S N Kabir Journal: Hum Reprod Date: 2004-06-24 Impact factor: 6.918
Authors: B A Lessey; I Yeh; A J Castelbaum; M A Fritz; A O Ilesanmi; P Korzeniowski; J Sun; K Chwalisz Journal: Fertil Steril Date: 1996-03 Impact factor: 7.329
Authors: Michael J Murray; William R Meyer; Richard J Zaino; Bruce A Lessey; Debra B Novotny; Karen Ireland; Donglin Zeng; Marc A Fritz Journal: Fertil Steril Date: 2004-05 Impact factor: 7.329
Authors: B A Lessey; A J Castelbaum; S W Sawin; C A Buck; R Schinnar; W Bilker; B L Strom Journal: J Clin Endocrinol Metab Date: 1994-08 Impact factor: 5.958
Authors: D A Budwit-Novotny; K S McCarty; E B Cox; J T Soper; D G Mutch; W T Creasman; J L Flowers; K S McCarty Journal: Cancer Res Date: 1986-10 Impact factor: 12.701
Authors: Creighton E Likes; Leah J Cooper; Jessica Efird; David A Forstein; Paul B Miller; Ricardo Savaris; Bruce A Lessey Journal: J Assist Reprod Genet Date: 2019-01-04 Impact factor: 3.412
Authors: Emma Giuliani; Kirstin L Parkin; Bruce A Lessey; Steven L Young; Asgerally T Fazleabas Journal: Am J Reprod Immunol Date: 2014-05-08 Impact factor: 3.886
Authors: Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810
Authors: Jason M Franasiak; Kristin J Holoch; Lingwen Yuan; David P Schammel; Steven L Young; Bruce A Lessey Journal: Fertil Steril Date: 2014-03-29 Impact factor: 7.329